Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits

• US 7,897,343 B2
• Filed: 12/28/2007
• Issued: 03/01/2011
• Est. Priority Date: 06/06/1991
• Status: Expired due to Fees

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Pol, Maria Anthonis Joannes, Terpstra, Catharinus, Wensvoort, Gert, Meulenberg, Jacoba Maria Johanna, Moormann, Jacobus Maria Robertus
• Primary Examiner(s): SALIMI, ALI REZA
• Application Number:
  US11/966,036
• Publication Number:
  US 20080108107A1
• Time in Patent Office: 1,159 Days
• Field of Search: 435/6, 435/69.1
• US Class Current: 435/6.16
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/10 from RNA viruses
• CPC Class Codes: C12N 2770/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2770/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6888 for detection or identification of organisms
• CPC Class Codes: Y10S 424/815 Viral vaccine for porcine species, e.g. swine
• CPC Class Codes: Y10S 435/975 Kit

Abstract

Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.

Claims

1. A method of producing an immunogenic composition, the method comprising:

introducing a purified preparation containing a polynucleotide encoding at least one polypeptide encoded by one or more open reading frames (ORFs) of ORFs 1-7 of a mystery swine disease virus wherein the polypeptide is one of more of the polypeptides selected from the group consisting of SEQ ID NO;

2;

SEQ ID NO;

3;

SEQ ID NO;

4;

SEQ ID NO;

5;

SEQ ID NO;

6;

SEQ ID NO;

7;

SEQ ID NO;

8 and SEQ ID NO;

9, into a suitable host cell,

culturing said suitable host cell; and

isolating one of the following therefrom;

a suitable host cell containing said polypeptide;

viral protein;

or viral polynucleic acid.

2. The method according to claim 1, further comprising isolating at least one of a cultured host cell and a polypeptide encoded by said polynucleotide.

3. The method according to claim 1, wherein introducing a purified preparation containing a polypeptide encoding at least one polypeptide encoded by one or more open reading frame (ORFS) of ORFS 1-7 of a mystery swine disease virus, into a suitable host cell comprises infecting the suitable host cell with a virus comprising a polynucleotide that encodes said polypeptide.

4. The method according to claim 1, wherein the mystery swine disease virus is characterized as being specifically reactive with serum antibodies of a sow, said serum antibodies obtained by intranasally inoculating a specific pathogen free sow with two milliliters of the virus identified as deposit number 11 102, deposited Jun. 5, 1991 with the Insitut Pasteur, Paris, France (at passage level 3, titer 1 04,8TCID.sub.so/milliliter) and collecting serum antibodies from the thus inoculated sow after 25 to 33 days.

5. The method according claim 3, further comprising isolating at least one of a cultured host cell and a polypeptide encoded by said polynucleotide.

6. The method according to claim 4 wherein said polynucleotide comprises a sequence selected from the group consisting of nucleotides 212-7399 of SEQ ID NO:

1;

7384-11772 of SEQ ID NO;

1;

11786-12532 of SEQ ID NO;

1;

12394-13188 of SEQ ID NO;

1;

12556-13188 of SEQ ID NO;

1;

12936-13484 of SEQ ID NO;

1;

12981-13484 of SEQ ID NO;

1;

13068-13484 of SEQ ID NO;

1;

13484-14086 of SEQ ID NO;

1;

14077-14595 of SEQ ID NO;

1; and

14588-14971 of SEQ ID NO;

1.

7. The method of claim 1, wherein said method comprises isolating one or more polynucleotides having a sequence selected from the group consisting of selected from the group consisting of nucleotides 212-7399 of SEQ ID NO:

1;

7384-11772 of SEQ ID NO;

1;

11786-12532 of SEQ ID NO;

1;

12394-13188 of SEQ ID NO;

1;

12556-13188 of SEQ ID NO;

1;

12936-13484 of SEQ ID NO;

1;

12981-13484 of SEQ ID NO;

1;

13068-13484 of SEQ ID NO;

1;

13484-14086 of SEQ ID NO;

1;

14077-14595 of SEQ ID NO;

1; and

14588-14971 of SEQ ID NO;

1.

8. The method of claim 1, wherein said method comprises isolating one or more of ORF polypeptides selected from the group consisting of the group consisting of SEQ ID NO:

2;

SEQ ID NO;

3;

SEQ ID NO;

4;

SEQ ID NO;

5;

SEQ ID NO;

6;

SEQ ID NO;

7;

SEQ ID NO;

8 and SEQ ID NO;

9.

9. A method of producing an immunogenic composition, the method comprising:

introducing a purified preparation containing a polynucleotide encoding at least one polypeptide encoded by one or more open reading frames (ORFS) of a mystery swine disease virus that has nucleotide sequence of SEQ ID NO;

1, into a suitable host cell,

culturing said suitable host cell; and

isolating one of the following therefrom;

a suitable host cell containing said polypeptide;

viral protein;

or viral polynucleic acid.

10. The method of claim 9, wherein said method comprises encoding one or more of ORF polypeptides selected from the group consisting of the group consisting of SEQ ID NO:

2;

SEQ ID NO;

3;

SEQ ID NO;

4;

SEQ ID NO;

5;

SEQ ID NO;

6;

SEQ ID NO;

7;

SEQ ID NO;

8 and SEQ ID NO;

9.

11. The method of claim 9, wherein said method comprises isolating one or more polynucleotides having a sequence selected from the group consisting of selected from the group consisting of nucleotides 212-7399 of SEQ ID NO:

1;

7384-11772 of SEQ ID NO;

1;

11786-12532 of SEQ ID NO;

1;

12394-13188 of SEQ ID NO;

1;

12556-13188 of SEQ ID NO;

1;

12936-13484 of SEQ ID NO;

1;

12981-13484 of SEQ ID NO;

1;

13068-13484 of SEQ ID NO;

1;

13484-14086 of SEQ ID NO;

1;

14077-14595 of SEQ ID NO;

1; and

14588-14971 of SEQ ID NO;

1.

12. The method of claim 9, wherein said method comprises isolating one or more of ORF polypeptides selected from the group consisting of the group consisting of SEQ ID NO:

2;

SEQ ID NO;

3;

SEQ ID NO;

4;

SEQ ID NO;

5;

SEQ ID NO;

6;

SEQ ID NO;

7;

SEQ ID NO;

8 and SEQ ID NO;

9.